SYGNIS AG signs supply agreement with US Biological for the Lightning-Link® antibody labelling technology
November 28th, 2017
Heidelberg, Germany and Cambridge, UK, 28 November 2017 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has signed a supply agreement with US Biological, Salem, MA, USA, for its Innova Lightning-Link® technology.
Heikki Lanckriet, CEO and CSO of SYGNIS AG, commented: “We are delighted that US Biological has chosen Lighting-Link® as its preferred method for antibody labelling. The technology has clear advantages in terms of simplicity and reproducibility, which will ultimately benefit US Biological’s customers by increasing the range of products available.”
US Biological is a global manufacturer and distributor of bioreagents, offering world-wide distribution of over 1,000,000 antibodies, biochemicals, biologicals, cell culture media, research kits and molecular biology bioreagents. The Company will use Lightning-Link® as its preferred antibody conjugation technology to expand its existing catalogue by enabling the production of additional labels, and allowing the company to address a broader range of markets. In addition to core labels for the Lightning-Link® range (horseradish peroxidase, alkaline phosphatase, and Fluorescein), the agreement gives US Biological the option to access the full range of Innova-branded products, including Europium and gold nanoparticles.
Lightning-Link® antibody and protein labelling technology provides the world’s fastest, easiest to use and most efficient method of antibody conjugation, offering highly stable antibody and protein conjugation with only 30 seconds hands-on time, and no separation steps. Lightning-Link® can make a range of assays easier, quicker and more sensitive, and contribute to reduced project costs. Lightning-Link® technology offers consistently high quality and easy scalability, with excellent batch-to-batch reproducibility, leading to reduced manufacturing costs.
About SYGNIS AG: www.sygnis.com
SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and proteomics research based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With applications spanning the entire molecular biology workflow, the Group’s cutting-edge offerings include easy-to-use off-the-shelf products as well as custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS’ products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the Expedeon, Expedeon and C.B.S. Scientific brands. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).